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Originally isolated from bone marrow, mesenchymal stromal cells (MSCs) have since been obtained from
various fetal and post-natal tissues and are the focus of an increasing number of clinical trials. Because of
their tremendous potential for cellular therapy, regenerative medicine and tissue engineering, it is desir-
able to cryopreserve and bank MSCs to increase their access and availability. A remarkable amount of
research and resources have been expended towards optimizing the protocols, freezing media composi-
tion, cooling devices and storage containers, as well as developing good manufacturing practices in order
to ensure that MSCs retain their therapeutic characteristics following cryopreservation and that they are
safe for clinical use. Here, we ﬁrst present an overview of the identiﬁcation of MSCs, their tissue sources
and the properties that render them suitable as a cellular therapeutic. Next, we discuss the responses of
cells during freezing and focus on the traditional and novel approaches used to cryopreserve MSCs. We
conclude that viable MSCs from diverse tissues can be recovered after cryopreservation using a variety of
freezing protocols, cryoprotectants, storage periods and temperatures. However, alterations in certain
functions of MSCs following cryopreservation warrant future investigations on the recovery of cells
post-thaw followed by expansion of functional cells in order to achieve their full therapeutic potential.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mesenchymal stromal cells (MSCs) have emerged as a promi-
nent candidate for cell-based therapies, tissue repair and immune
modulation. Intensive research has been directed at elucidating
their characteristics and the mechanisms by which they elicit their
therapeutic effects. Translating basic research to clinical applica-
tions for a wide range of degenerative diseases and autoimmune
disorders requires a steady supply of viable and functional cells.
Following the example of hematopoietic stem/progenitor cells,
which have been previously cryopreserved and successfully
transplanted at a later time, MSCs can likewise be stored and
thawed as needed. The challenge becomes the optimization of
freezing protocols to ensure that MSCs retain the characteristics
of their freshly isolated counterparts.
In this review we begin with a brief historical background on
the identiﬁcation and characterization of MSCs and the tissues,apart from bone marrow, from which they have been derived.
The rationale for cryopreservation of MSCs for cellular therapy
and tissue engineering applications is then discussed. We describe
the cryobiological responses of cells and tissues, including the
two-factor hypothesis of cryoinjury and the roles of cooling rates
and cryoprotective agents in mitigating freezing-induced damage.
We focus on the traditional and novel approaches that have been
employed to cryopreserve MSCs and the current status of MSC
manufacturing, banking and clinical transplantation. We recognize
that variability in outcome of MSC-based clinical trials is likely not
due to differences in the manner by which MSCs from various
sources are cryopreserved, but rather to alterations in some of
the crucial functional characteristics of MSCs following their
cryopreservation.
2. Mesenchymal stromal cells (MSCs)
2.1. Identiﬁcation and characterization
Nearly half a century ago, Friedenstein and colleagues observed
spindle-shaped cells with dense cytoplasm and large nuclei in
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into polygonal cells with characteristic features of osteoblasts or
bone-forming cells [69]. Thus, it became apparent that aside from
the blood-forming (hematopoietic) stem cells, non-hematopoietic
cells exist in the bone marrow, which are capable of generating
colony-forming unit-ﬁbroblasts having osteogenic potential. In
1991, Caplan introduced the term ‘‘mesenchymal stem cells’’
(MSCs) to designate cells in the ‘‘mesoderm’’ (middle germ layer)
from which bone, cartilage, tendon, ligament, fat, skin, muscle,
and marrow stroma are derived [30]. This terminology has been
criticized and deemed technically inappropriate because the origi-
nal concept ofMSCs speciﬁcally referred to cells in the bonemarrow
having limited self-renewal and differentiation capacity, whereas
the current notion has been extended to include cells from almost
every post-natal tissue to which stem cell characteristics have been
ascribed [22]. However, in consideration of the widespread usage of
the acronym MSCs, throughout this review we will use the same
abbreviation but refer to these cells as ‘‘mesenchymal stromal
cells.’’ Moreover, in recognition of the fact that the therapeutic
potential ofMSCs rely on tissue-speciﬁc characteristics of these cells
we will always indicate the tissue from which they were derived.
From their initial isolation until now, it has been widely
accepted that primary MSC cultures are a heterogeneous popula-
tion of cells with varying capacities of self-renewal and differentia-
tion [91,131,162]. Due to a lack of unique markers, MSCs have been
minimally deﬁned using criteria based on their propensity to
adhere to the plastic surface of culture vessels, expression of
CD73, CD90 and CD105, absence of CD34, CD45, CD14 and
HLA-DR, and by their tri-lineage differentiation into adipocytes,
chondrocytes and osteocytes under inductive culture conditions
[51]. These properties persist during the cultivation of MSCs inde-
pendent of the degree of cell conﬂuence during expansion [83]. In
view of the functional potency of MSCs as immune modulators, a
standardized assessment of their immunological properties has
also been proposed [115]. Despite these attempts to establish the
identity of MSCs, confounding issues remain such as the similarities
that MSCs share with stromal ﬁbroblasts [87], and with pericytes
that closely enfold endothelial cells in capillaries and microvessels
[131]. Controversies aside, the versatility of MSCs has generated
remarkable interest for applications in cellular therapy, regenera-
tive medicine and tissue engineering. In fact, to date over 500 clin-
ical trials are testingMSCs as therapy for a diverse range of diseases
(Fig. 1), although less than 2% of these studies have published
results (http://www.clinicaltrials.gov). Interestingly, the mostFig. 1. MSCs are increasingly being tested as therapy for a diverse range of diseases.
This graph summarizes the number of clinical trials as reported on the website
http://www.clinicaltrials.gov (Accessed 2015 Jan 28). GVHD (graft-versus-host
disease).promising applications are those of bone marrow-derived MSCs
for disorders of the bone and cartilage [156]. It is now increasingly
recognized that tissue regeneration induced by MSCs may be con-
tingent upon the tissue from which they were derived.
2.2. Tissue sources
Bone marrow has been for many years the main source of MSCs,
but its collection from patients and donors is an invasive and
painful procedure. Moreover, there is only a very low frequency
(0.001–0.01%) of MSCs in bone marrow and these numbers decline
with age [31,123]. MSCs were shown to be present in essentially all
adult murine organs and tissues [189]. A rational explanation
proposed for this observation is that any tissue that is able to repair
itself must harbor a reserve of progenitor cells that can contribute
to the renewal and replenishment of cells in that tissue [151].
There is also emerging evidence for the perivascular origin of
MSCs, as they have been shown to assemble around blood vessels
[36,40,42]; thus, any tissue or organ where blood ﬂows will natu-
rally have MSCs closely associated with or adhering to vascular
walls. MSCs have been isolated from multiple adult human tissues
such as adipose tissue [81,220], articular cartilage [4,90], brain
[8,157], dental tissues [47,80,154,158,207], endometrium and
menstrual blood [192,199] and skin [172]. In addition, perinatal
organs and tissues that are generally discarded after delivery,
namely amniotic ﬂuid [6,197], amniotic membrane [111], placenta
[5,97], Wharton’s jelly [15,110], umbilical cord tissue [180,215]
and cord blood [23,59,132] have been shown to be rich sources
of proliferative MSCs. Among these, cord blood has been cryopre-
served and banked as a source of transplantable hematopoietic
stem/progenitor cells for patients with hematological disorders
[13]; however, the existence of non-hematopoietic MSCs in cord
blood could shift the paradigm and expand its utilization in cellular
therapy.
2.3. Properties of MSCs useful for cellular therapy
2.3.1. Proliferation capacity
The precursor cells for osteogenic tissue that Friedenstein’s
group described in their seminal papers [69,70] were characterized
by high mitotic activity. The ability of MSCs to proliferate in vitro is
traditionally evaluated using a colony forming unit-ﬁbroblast
assay or by measuring the population doubling time. MSCs exhibit
a typical growth curve consisting of an initial lag phase followed by
a logarithmic phase and lastly a senescent phase. Under optimal
conditions, during the log phase of growth (around passages 2–
4), MSCs can easily be expanded upwards of 50 population dou-
blings making it possible to attain therapeutic doses. For example,
for clinical application in graft-versus-host disease at least 1–
2  106 MSCs per kg of patient body weight is generally adminis-
tered by systemic infusion twice per week over the course of
2 weeks [107,171].
2.3.2. Differentiation potential
Aside from bone, MSCs derived from bone marrow can differen-
tiate into other mesodermal lineages such as cartilage, adipocytes
and connective stromal cells when cultured under appropriate
induction media formulations [163]. Similar to the hierarchical
differentiation of hematopoietic cells, bone marrow-derived
MSCs undergo a mesengenic process as they differentiate to these
lineages and to tendon, ligament and muscle [31]. For example,
bone marrow and adipose tissue-derived MSCs have been primed
to differentiate to cardiomyocytes, and this ﬁnding has been trans-
lated into clinical trials for cardiovascular repair [160,167].
However, the underlying mechanism appears to be the secretion
of biomolecules that can stimulate tissue regeneration by resident
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MSCs might be capable of transcending germ layer boundaries and
differentiating into ectodermal lineage cells such as neurons [217],
and into endodermal lineage cells such as hepatocytes [100];
however, there is accumulating evidence against this idea of
trans-differentiation [21]. In fact, recent evidence suggests that
MSCs are unlikely to induce tissue regenerative processes by
in situ differentiation or by directly replacing damaged cells [16].
Although not endowed with their previously touted pluripotency,
MSCs are nevertheless recognized to exert therapeutic effects
through other mechanisms.
2.3.3. Release of bioactive factors
MSCs secrete a wide array of growth factors and cytokines
which can exert autocrine effects (in which the secreted molecules
interact with receptors on the same cell) or paracrine effects (in
which the secreted molecules interact with other cells). These
interactions can promote the formation of new blood vessels and
re-establish blood supply (angiogenic), prevent programmed cell
death (anti-apoptotic), stimulate progenitors to divide (mitotic),
prevent scarring (anti-ﬁbrotic), recruit resident progenitor cells
(chemotactic) or provide the microenvironment favoring the
differentiation of resident stem cells (cooperative) [32,190]. In
addition, MSCs possess broad immunomodulatory properties, by
which they can sense and control inﬂammation [20].
2.3.4. Immunoregulatory properties
At the onset of inﬂammation, endogenous MSCs are activated to
secrete soluble factors that inhibit the proliferation of T cells and
mount an anti-inﬂammatory response [58,166]. In contrast to this
immunosuppressive response, allogeneic MSCs may elicit an
innate immune response by releasing chemokines that recruit
macrophages, neutrophils and lymphocytes to sites of inﬂamma-
tion [7,121,188]. MSCs have been shown to affect other cells of
the immune system including B cells, NK cells, dendritic cells
and macrophages [190]. In order to exert their effects, MSCs need
to migrate to inﬂammatory sites.
2.3.5. Migratory properties
MSCs communicate with other cells in the human body and
appear to ‘‘home’’ to areas of injury in response to signals of cellu-
lar or tissue damage [48,105]. Whereas tracking studies have
shown that a majority of MSCs get trapped in the lungs following
intravenous infusion, they tend to disappear from the lungs within
hours and migrate to other tissues such as the liver, spleen and kid-
ney, and preferentially to sites of injury [9,37,120]. Despite their
limited lifespan, it is believed that MSCs can exert their therapeutic
effects via other cell types [55]. The mode of recruitment of MSCs is
by chemotaxis, a directional migratory response to a gradient of
soluble chemoattractants. We and others have shown that stromal
cell-derived factor (SDF)-1, a chemokine that is up-regulated in
sites of injury, is critical for the chemotaxis of MSCs through its
interaction with its receptor CXCR4 [126,191]. Moreover, we also
found that the expression of CXCR4 in human cord-blood derived
MSCs can be enhanced in order to improve their efﬁcacy for tissue
repair [133–135,168].
2.4. Clinical and tissue engineering applications of MSCs
Applications of MSCs for cellular therapy and regenerative
medicine have been the subject of numerous reviews
[46,65,139,171,186,196,198]. Their availability, ease of expansion,
and amenability to genetic or tissue engineering manipulations
make MSCs particularly attractive for cellular therapy applications.
As discussed above, the therapeutic efﬁcacy of MSCs appears to be
derived from their ability to secrete a broad range of bioactivemolecules that are immune-modulatory, anti-apoptotic,
anti-ﬁbrotic, anti-inﬂammatory, pro-angiogenic, chemotactic or
stimulatory of tissue regeneration in response to injury
[26,52,118,170,190]. It appears that MSCs are able to detect injury
and inﬂammation and concomitantly activate multiple restorative
pathways in response to local stimuli from the injured tissue by
releasing growth factors, chemokines, enzymes, etc. that induce
the resident progenitor cells in the tissue to repair itself.
The secretory nature of MSCs can further be exploited by genet-
ically manipulating MSCs to express missing or defective proteins
in patients with congenital or acquired deﬁciency disorders. For
example, we have modiﬁed cord blood-derived MSCs using lentivi-
ral transduction to express coagulation Factor IX for potential
transplants in hemophilia B patients [49]. Furthermore we have
encapsulated Factor IX-engineered MSCs in ﬁbrinogen–alginate
microcapsules and shown them to have enhanced cell viability
and Factor IX secretion [182]. The use of MSCs as vehicles for deliv-
ering proteins via exosomes for therapeutic purposes such as glial
cell-derived neurotrophic factor for Parkinson’s disease, nerve
growth factor for Alzheimer’s disease and brain-derived neu-
rotrophic factor for Huntington’s disease have also been explored
[211]. In the setting of allogeneic hematopoietic stem cell
transplantation, MSCs have been used to promote engraftment
and for immunosuppression in graft-versus-host disease
(GVHD) [25,94,196,214]. In fact, the ﬁrst commercially available
MSC therapeutic approved by Health Canada, Prochymal
(Osiris Therapeutics, Inc., Columbia, MD, recently acquired by
Mesoblast, Melbourne, Australia), is indicated for the management
of GVHD.
Prochymal has demonstrated immunomodulatory properties to
regulate T-cell-mediated inﬂammatory responses by inhibiting
T-cell proliferation and down-regulating the production of the
pro-inﬂammatory cytokines such as tumor necrosis factor-alpha
and interferon gamma. It is marketed as a cell suspension of
ex vivo expanded adult human bone marrow-derived MSCs, sup-
plied as a 15-mL formulation with approximately 100  106 viable
cells in Plasma-Lyte A containing 5% human serum albumin and
10% dimethyl sulfoxide (Me2SO). The doses are packaged in
Cryocyte freezing containers and frozen for storage (24-month
shelf-life) at liquid nitrogen (LN2) vapor phase temperature
(6135 C) until thawed and reconstituted before administration.
The reconstituted product can be kept at room temperature and
used within 5 h post-thaw. Prochymal is an example of how
MSCs may be supplied as an off-the-shelf product by employing
cryopreservation techniques. In a recent review of 49 clinical trials
testing MSCs for various disorders, 35% employed MSCs that have
been cryopreserved [98]. However, as we will discuss later, mixed
outcomes, negative ﬁndings, or results showing only minimal or
transient improvements in patients indicate that the post-thaw
functionality of cryopreserved MSCs may be a factor contributing
to their efﬁcacy.
2.5. Rationale for cryopreservation of MSCs
The cryopreservation of primary cells has been extensively used
in hematopoietic stem cell transplantation. In autologous patients,
the cells are collected and cryopreserved for later clinical use. In
allogeneic patients, cryopreservation permits the banking of cells
for human leukocyte antigen typing and matching, facilitates the
logistical transport of cellular products to transplant centers, and
allows sufﬁcient time for the screening of transmissible diseases
in the donated cells before transplantation. Cryopreservation of
MSCs can likewise reduce the constant need for fresh tissues,
enable quality control and standardization of the same cell prepa-
ration at different times when the cellular product is needed, and
provide a source of reference MSCs that can be used to validate
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able a ready off-the-shelf supply of cells for transplant, as well as
allow better timing of therapy. It is essential to cryopreserve
MSCs at an early passage in order to maintain a reservoir of healthy
and efﬁcacious cells for transplant, as the number of MSCs and
their differentiation potential decrease with passage [203]. In fact,
patients treated with MSCs at early passage had improved clinical
outcome over those given late-passage cells [147]. Moreover, some
MSCs, such as those derived from human amniotic membrane, can-
not survive for long periods of culture [148]. In addition, MSCs
under long-term ex vivo culture conditions could be prone to geno-
typic drift, chromosomal aberrations, phenotypic instability and
contamination [18,200]. Cryopreservation could circumvent these
problems and also save time and culture media. There have also
been studies demonstrating that fetal MSCs harvested in the pre-
natal period can be cryopreserved during the remainder of the ges-
tation period to be used for the repair of congenital disorders soon
after birth or in utero [116,119]. Clearly, the ﬁelds of tissue engi-
neering, gene therapy, regenerative medicine and cell transplanta-
tion rely to a great degree on the ability to preserve, store and
transport these cells. In addition, a master cell bank of reference
MSCs from various tissue sources could be important to advance
research and clinical translation [202]. Ironically, the same cryop-
reservation process aimed at preserving living cells could also
cause damage and compromise their survival. An understanding
of the responses of cells and tissues to the physical changes that
occur during the freezing process is essential in the design of pro-
tocols that will minimize cryoinjury and ensure maximum recov-
ery of viable and functional cells.3. Cryobiological responses of cells
3.1. Role of cooling rates
The purpose of cryopreservation is to maintain life by slowing
down metabolic activity of cells at temperatures as low as that of
liquid nitrogen (196 C). Several mechanisms have been
proposed to explain cell behavior during cryopreservation. In the
course of freezing cells in suspension, water crystallizes in pure
form in the extracellular space, resulting in the concentration of
dissolved solutes in the remaining liquid. A concentration gradient
is created across the cell membrane and, if cooling takes place
slowly enough, water moves out of the cells in response to the
resultant osmotic stress. As cooling continues and more ice is
formed, salts concentrate to high levels as the cells become
dehydrated and shrink. Damage caused by extended exposure to
increased solute concentration at intermediate temperatures is
referred to as slow-cooling injury. On the other hand, if the cooling
rate is too fast for the cells to maintain equilibrium by loss of
intracellular water, the unfrozen solution within the cells
becomes increasingly super-cooled resulting in intracellular ice
formation. Damage caused by intracellular ice is referred to
as rapid-cooling injury. This two-factor hypothesis of freezing
injury (i.e., solute effects and intracellular ice formation) as
proposed by Mazur [140] has been elaborated upon by others
[66,75,144,150,175,176]. Successful cryopreservation of cells in
suspension requires sufﬁciently high cooling rates to reach low
temperatures quickly, minimize solution effects and avoid
slow-cooling injury, but low enough cooling rates to decrease
the formation of intracellular ice and avoid rapid-cooling injury.
A cell will proceed towards osmotic equilibrium by allowing water
to get in or out until there is no osmotic gradient across the
plasma membrane. However, these osmotic volume excursions
can exceed the tolerance limits of cells, as shown in cord
blood-derived CD34+ cells [96], adding a third prominent injurymechanism to the slow-cooling and rapid-cooling injuries
described above.
It is important to consider that different cell types have differ-
ent membrane permeability parameters and therefore, it is logical
that responses of cells to cooling rates are also cell-type speciﬁc.
For example, optimal cooling rates range from 1 C/min for mouse
marrow stem cells to over 1000 C/min for human red blood cells
[141]. Also, conﬂuent monolayers that have intercellular connec-
tions called gap junctions form more intracellular ice at a given
temperature compared to cells that do not have gap junctions
[1], and it has recently been recognized that the inﬂuence of cell
junctions on intracellular ice is extremely complex [56,89].
Moreover, it was shown for dental pulp-derived MSCs that intra-
cellular ice formation does not cause cell membrane rupture but
rather protects the cells from dehydration during freezing [219].
In another study comparing bone marrow-derived MSCs from var-
ious species, the highest post-thaw cell viability was obtained in
mouse MSCs (91.5 ± 5.6%) while the lowest was in human MSCs
(82.9 ± 4.3%) [128]. These results highlight the importance of cellu-
lar characteristics in determining response to freezing. Because
mouse MSCs are smaller and have higher surface-to-volume ratio
than human MSCs (0.65 lm1 vs. 0.34 lm1) mass transfer occurs
faster in mouse MSCs which inﬂuences their survival rate [128].
In addition to controlling the cooling rates, cryoprotectants
have been added to cell suspensions to minimize the damaging
effects of freezing.3.2. Role of cryoprotectants
Cryoprotectants are classiﬁed as either permeating or
non-permeating depending on their ability to traverse the cell
membrane [143]. Permeating cryoprotectants, such as Me2SO,
glycerol, ethylene glycol, propylene glycol (1,2-propanediol),
methanol, ethanol, propanol and formamide, protect against slow
cooling injury by reducing extracellular ice formation, preventing
excessive concentration of solutes and minimizing cell dehydra-
tion to a tolerable degree [129]. Their protective property is shared
bymany lowmolecular weight compounds having a high solubility
in aqueous solutions and which, at high multi-molar concentra-
tions, are able to depress the freezing point of water, thereby
reducing the amount of ice formed at any temperature during cool-
ing [142,145]. The rate at which a given one of these compounds
penetrates the cells varies for different cell types and cell sources
[143]. Non-permeating cryoprotectants can protect cells at lower
molar concentrations, but they generally require more rapid rates
of freezing to confer protection [143]. Examples include
polyvinylpyrrolidone, sugars such as trehalose, sucrose, lactose
and glucose, sugar alcohols such as mannitol and sorbitol, and
the polymer hydroxyethyl starch (HES). Many mechanisms of
action of non-permeating cryoprotectants have been proposed
[29,142,143]. For example, because HES does not penetrate the
cells, its extracellular concentration increases, creating an osmotic
stress on cells which results in a loss of intracellular water at high
subzero temperatures. In other words, non-permeating cryopro-
tectants remove water from the cells primarily during the initial
phases of freezing when they are concentrated in the extracellular
regions [142]. The cryoprotective effects of trehalose have been
attributed to its interactions with lipid membranes, stabilization
of proteins during freezing–thawing processes, and its ability to
form a glassy matrix that can contribute to the inhibition of poten-
tially lethal intracellular ice [29].
Although intended to confer protection as their name implies,
cryoprotectants can also cause injury to cells and several investiga-
tions have focused on determining, minimizing or eliminating their
toxicity [3,57,60,62–64,103].
L.A. Marquez-Curtis et al. / Cryobiology 71 (2015) 181–197 1854. Approaches to cryopreservation of MSCs
4.1. Conventional methods of MSC cryopreservation
MSCs for clinical use are most commonly frozen in 5% or 10%
Me2SO in an electrolyte solution (e.g. Plasmalyte) with an added
protein (e.g. human serum albumin). The freezing rate is typically
1 C/min to 5 C/min until roughly 100 C at which point the cells
are placed in liquid nitrogen or its vapor-phase [84]. However, this
procedure is based on the cryopreservation protocols developed for
hematopoietic stem cells and lymphoid cells and is not optimized
for MSCs [186]. It is important to consider that the parameters that
are crucial in mitigating cell damage during cryopreservation are
not only dependent on whether the cells are in suspension or in
an adherent monolayer, but also on the cell source. For example,
it was shown that when suspended and adherent human bone
marrow-derived MSCs were cooled at 1/min to 80 C and stored
in liquid nitrogen, the post-thaw viability was 30–35% lower in the
adherent cells [212,213]. In addition, post-thaw viabilities of cells
isolated from different tissue sources differed signiﬁcantly, with
adipose tissue being a more robust stem cell source than dental
pulp and bone marrow [44]. Therefore, an understanding of the
physical and biological processes that take place when cells are fro-
zen and thawed is essential in developing protocols to ensure that
MSCs maintain their structural integrity and retain their functional
properties.4.2. Effects of cooling rates, cryoprotectants, storage period and
temperature on the characteristics and function of cryopreserved MSCs
Several studies have shown that MSCs from diverse sources can
be cryopreserved in different ways using different cryoprotectants
and employing various cooling rates, storage periods, and temper-
atures without compromising their proliferation potential, pheno-
typic characteristics and capacity for differentiation (Table 1).
These investigations were focused on optimizing cell survival and
function and ensuring that cryopreserved MSCs display the same
characteristics as freshly isolated cells.
As early as 1997 it was shown that human bone
marrow-derived MSCs that were cryopreserved in 10% Me2SO
(with an unspeciﬁed cooling proﬁle) and stored in liquid nitrogen
for 24 h can be sub-cultured for up to 15 passages and still retain
their osteogenic potential [28]. Later, it was likewise demonstrated
that osteoblast progenitor cells derived from human bone marrow
aspirates – cryopreserved by cooling 1 ml cell suspension in 10%
Me2SO at 1 C/min to 70 C and after 24 h, storing in liquid nitro-
gen for 7 days – exhibit no signiﬁcant difference in their prolifera-
tion rate and osteogenic potential compared to cells from fresh
bone marrow [179].
Because of loss in replicative ability with extensive passaging,
many subsequent investigations focused on cryopreservation of
MSCs at an early passage. For instance, human bone marrow
mononuclear cells were either plated immediately (MSC-Passage
1) or frozen in 1 mL cryovials in the presence of 5% Me2SO and
10% fetal bovine serum (FBS) using an unspeciﬁed cooling protocol
and stored for a week in liquid nitrogen and then thawed, cultured
(F-MSC-P1) and analyzed [82]. The MSC-P1 was either analyzed
directly or frozen for a week, then thawed, cultured
(F-MSC-Passage 2) and analyzed. All batches of cells were
shown to have similar morphology, proliferation potential and
surface marker expression [82]. In another study, rabbit
synovium-derived MSCs were expanded up to passage 5 and
cryopreserved in 1 mL of commercial freezing media (CellBanker,
Fukushima, Japan). Cryovials were placed in a cryofreezing con-
tainer and then stored at 80 C for 1 week. The cryopreservedMSCs showed no signiﬁcant difference in viability (as measured
by the spectrophotometric MTT assay), proliferation rate and
expression of chondrogenic genes compared to fresh MSCs [153].
To investigate the effect of cryoprotectants on the post-thaw
properties of MSCs different combinations of Me2SO (1%, 4%, 8%
and 10%) and trehalose (9%, 6% and 2%) in 90% FBS were tested
on human adipose tissue-derived MSCs [173]. After adding 1 mL
of freezing solution in 1.8 mL cryovials, the cells underwent uncon-
trolled cooling by placing directly at 20 C for 30 min, then plac-
ing at 80 C for 1 h, and were ﬁnally transferred into liquid
nitrogen (196 C) for long-term storage (1, 6 and 12 months).
The best freezing solution, composed of 4% Me2SO and 6% tre-
halose, resulted in cells with more than 80% post-thaw viability
as measured by ﬂow cytometry using an annexin/propidium iodide
assay kit. Furthermore, proliferation of cryopreserved MSCs was
comparable to that of fresh cells; no apoptotic death was observed,
and cells retained their differentiation multipotency. Finally, in the
same study, the adherent cell population after long-term cryop-
reservation gave rise to MSCs with morphology, immunopheno-
type, proliferation, and differentiation potential similar to those
of fresh cells [173].
Similarly, in an attempt to optimize the cryopreservation of
dental pulp-derived MSCs, the cells were frozen in various concen-
trations (0.5, 1.0 and 1.5 M) of ethylene glycol, propylene glycol or
Me2SO using a cooling rate of 1 C/min to 85 C followed after
24 h by immersion in liquid nitrogen [207]. The viability (as mea-
sured by a trypan blue exclusion assay) of cells frozen in 1.0 M and
1.5 MMe2SO were signiﬁcantly better (about 91 ± 9%) than the via-
bility of cells frozen in the other cryoprotectants. The use of 1.3 M
Me2SO (about 10% w/v) worked as well as the commercially avail-
able cryoprotectant containing 10% Me2SO in a serum-free deﬁned
medium (Cryostor CS-10, BioLife Solutions Inc., Bothell, WA).
Furthermore, MSCs did not show statistically signiﬁcant differ-
ences in their doubling times during their log-phase of growth,
or in their expression of surface markers whether they were stored
at 85 C (mechanical freezer) or at 196 C (liquid nitrogen
Dewar) for up to 6 months [207].
To further compare the effect of cryoprotectant, either 10%
Me2SO, 10% glycerol or 10% ethylene glycol was added to 90%
FBS to cryopreserve human dental root-derived MSCs [47]. Cells
at a concentration of 1  106/mL were slowly cooled by placing
cryovials directly at 4 C for 1 h, followed by uncontrolled cooling
at 20 C for 2 h, then at 80 C overnight and ﬁnally at 196 C
for 6 months. There were no signiﬁcant differences observed
between fresh and cryopreserved MSCs in terms of cell viability
(by trypan blue exclusion), colony-forming efﬁciency, proliferation
rate, differentiation, phenotypic and karyotypic proﬁles and
immunological responses [47].
In addition to cryoprotectant effects, various cooling rates and
storage periods in liquid nitrogen have also been investigated.
Amniotic ﬂuid-derived MSCs were subjected to time-programmed
slow cooling (consisting of 1 C/min to 60 C, then 3 C/min to
100 C followed by liquid nitrogen storage for 3 and 6 months)
or a non-programmed protocol (consisting of cooling for 20 min
in a 20 C freezer, followed by 12–16 h in a 80 C freezer, and
storage in liquid nitrogen for 3 or 6 months) [99]. The cryoprotec-
tants used were Me2SO (5% or 10%), glycerol (5% or 10%), sucrose
(30 or 60 mM), or trehalose (60 and 100 mM). Interestingly, the
freezing protocols did not cause any signiﬁcant differences in
post-thaw cell viability as measured by trypan blue exclusion.
Moreover, all cryoprotectants tested were able to maintain the
surface marker expression, gene expression and differentiation of
MSCs, although more viable cells were recovered using Me2SO or
glycerol rather than sucrose or trehalose [99].
Using rat bonemarrow-derivedMSCs, it was shown that the rate
of freezing (slow cooling at 0.3 C/min or fast cooling at 99 C/min
Table 1
Studies on cryopreservation of MSCs from various tissues using different cryoprotectants, cooling protocols, storage temperatures and periods.
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L.A. Marquez-Curtis et al. / Cryobiology 71 (2015) 181–197 187to 100 C before storage at 134 C) affected neither phenotypic
markers in cryopreserved vs. fresh cells nor their ability to prolifer-
ate or differentiate into osteocytes [152]. The direct post-thaw via-
bility as assessed by the spectrophotometric metabolic activity
tetrazolium MTT assay was about 85% using other protocols which
included one to four-step cooling stages or a ‘‘straight freeze’’
approach which involved direct plunge in liquid nitrogen vapor
phase (134 C) after 10 min equilibration with cryoprotectant at
4 C. The effect of different cooling rates on viability became evident
only after 3 days of culture [152]. This was to be expected as it has
been shown that cryopreservation-associated apoptosis and necro-
sis occur hours to days after thawing as various pathways are acti-
vated [17]. It is also important to note that MTT may not give an
accurate numerical estimate of cell viability due to the increased
metabolic activity per cell after cryopreservation as reported for
WST-1 (a related tetrazolium assay) [102].
To test the effect of storage period, horse blood-derived MSCs
were cryopreserved in 10% Me2SO and 90% FBS (cooled at
1 C/min to 80 C and after 1 week transferred to liquid nitrogen)
and stored for 10–12 months [137]. Post-thaw analyses revealed
that MSCs retained their morphology, alkaline phosphatase and
telomerase activities, karyotype proﬁle, proliferation rate, expres-
sion of surface markers, and adipogenic, osteogenic and myogenic
potential. The latter is particularly important in veterinary medi-
cine as horses are susceptible to muscle injuries [137]. Likewise,
MSCs from porcine adipose tissue were cryopreserved in 10%
Me2SO using an unspeciﬁed cooling protocol and stored in liquid
nitrogen for up to 12 months [43]. The morphology, viability (as
measured by ﬂow cytometry using annexin/propidium iodide
staining), expression of surface markers, cumulative population
doublings and senescence rates were maintained after long-term
storage. Cryopreservation did not produce any chromosomal aber-
rations nor did it affect adipogenesis or osteogenesis [43]. The
effect of extended storage period was examined in another study
where human bone-marrow derived MSCs were frozen in a com-
mercially available Me2SO-containing freezing solution
(CellBanker, Tokyo, Japan) for up to 3 years [114]. First, the cells
were allowed to equilibrate at 4 C for 10 min, then cooled by
uncontrolled cooling at 30 C for 1 h, further cooled by placing
at 80 C for 2–3 days, then stored at 152 C. The viability of cry-
opreserved cells determined using an automated nuclei dye exclu-
sion cell counter was approximately 90% regardless of the length of
storage (0.3–37 months). Cryopreservation did not affect the
expression of surface markers and had no inﬂuence on the ability
of MSCs to undergo osteoblastic differentiation [114].
Aside from in vitro properties after cryopreservation, the reten-
tion of in vivo function of cryopreserved MSCs has also been inves-
tigated. Canine bone marrow-derived MSCs were subjected to a
3-step slow freezing procedure (uncontrolled cooling by placing
at 4 C for 1 h, followed by 2 h at 20 C, then 10.5 h at 80 C in
the presence of 10% Me2SO) before plunging into liquid nitrogen
[218]. After 3 years, the cells were thawed at 37 C, assessed for
viability by trypan blue staining and alkaline phosphatase activity,
and then seeded onto collagen scaffolds. The MSC-scaffold complex
was implanted into nude mice and was shown to retain osteogenic
differentiation ability [218]. In addition, MSCs from monkey bone
marrow that were cryopreserved (in CellBanker freezing medium
by placing directly at 80 C for 24 h and then kept in a 150 C
freezer for 10 days) and used in a quantitative implantation model
showed extra-skeletal bone formation similar to fresh MSCs [195].
Human bone marrow-derived MSCs that have been cryopre-
served in suspension have been thawed and cultured in 3D scaffolds
prior to their use in tissue repair. In one study, the cells were cryop-
reserved inmediumcontaining 10%Me2SO and20% FBS by exposing
to 4 C for 1 h, then placing at 20 C for 2 h, followed by rapid
freezing in liquid nitrogen. After 24 h the cells were quickly thawedat 37 C and seeded in partially demineralized bone matrix scaf-
folds. The cryopreserved MSCs exhibited the same proliferation
potential, alkaline phosphatase activity, osteocalcin secretion and
osteogenic differentiation in vitro and in vivo as fresh cells [125].
Although the cells were frozen for only a day, the authors expect
similar results for cells that are stored for a longer period.
In our lab we have been able to isolate MSCs from umbilical
cord blood and have sub-cultured and frozen them at different pas-
sages using uncontrolled cooling at 70 C in the presence of 10%
Me2SO and 10% FBS [168,191]. Cord blood was collected with the
mother’s informed consent in accordance with the guidelines of
the University of Alberta Health Research Ethics Board, and exper-
iments were conducted with their approval. For the purpose of this
review and reported in a poster [136], we evaluated MSCs derived
from one cord blood sample; from approximately 2  106 cells
from passage 1 cultures we were able to achieve close to 50 popu-
lation doublings and to generate several million cells in frozen
stocks from passages 2–6. We obtained post-thaw viability by try-
pan blue exclusion of 80 ± 10% from stocks frozen for 5 years and
89 ± 5% from stocks frozen for 2 years [136]. On sub-culture we
found that thawed cells retained their ﬁbroblastic morphology
and expression of CD73, CD90 and CD105 as determined by ﬂow
cytometry. Moreover, the cells exhibited an ability to differentiate
to osteoblasts and chondrocytes in vitro, as detected by Alizarin red
staining for calcium deposits and Alcian blue staining for proteo-
glycans, respectively. The expression of markers of pluripotency
(Nanog, Oct-4, Rex-1 and Sox-2) and differentiation (nestin, osteo-
calcin and collagen X) were conﬁrmed by RT-PCR [136]. We have
then proceeded to use these cells in our investigations aimed at
improving the in vitro migratory potential of MSCs [133–
135,168] and transducing these cells to produce Factor IX
[49,181,182]. Our studies demonstrated the high-efﬁciency recov-
ery of viable, proliferative and functional cells after cryopreserva-
tion which can be employed for research, gene therapy or clinical
transplantation.
Taken together, the above studies demonstrate that MSCs from
diverse sources, cryopreserved using different cooling rates, in the
presence of different cryoprotectants and stored for various
lengths of time and at various subzero temperatures retain their
biological properties post-thaw (Table 1). Indeed, MSCs have
shown robustness and resiliency during cryopreservation unlike
other cells which required optimal cooling rates [141] or deﬁned
protocols. For example, to achieve maximal recovery of functional
mouse oocytes, they had to be cryopreserved in 1.5 M Me2SO at a
cooling rate of 0.5 C/min and a plunge temperature of 80 C
[106]. In addition, whereas rabbit synovium-derived MSCs main-
tained their morphology and differentiation potential after storage
at 80 C in a commercial preservation solution, chondrocytes did
not [153]. We note that the hematopoietic cell line, TF-1, has also
shown robustness to cryopreservation protocols; it has even been
demonstrated using interrupted rapid cooling to 40 C that there
is a narrow range of hold temperatures (5 C to 12 C) and times
(1–6 min) that confers cryoprotection in the absence of added per-
meating cryoprotectant [174]. Notwithstanding this robustness of
MSCs to cryopreservation protocols, many groups have explored
other strategies to improve the cryopreservation of MSCs for the
purpose of reducing the toxicity of cryoprotectant, eliminating
animal-derived serum in the freezing solution, minimizing
freezing-induced cell damage or simulating the 3D conﬁguration
in vivo by using scaffolds.
4.3. Other strategies for MSC cryopreservation
4.3.1. Reducing Me2SO
Me2SO is the most widely used cryoprotectant for MSCs, but it
is potentially toxic at molar concentrations and has been shown to
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including nausea, headache, hypotension, hypertension, diarrhea
and abdominal cramps have been reported in patients infused with
Me2SO-containing hematopoietic stem cells [2,177]. Thus, it is
desirable to reduce Me2SO in cellular products for clinical use. It
has been shown that a human hematopoietic stem cell line can
be cryopreserved in the absence of Me2SO or any other permeating
cryoprotectant [174] with careful choice of cooling proﬁle [175]. To
this end, human adipose-derived MSCs were cryopreserved in
standard medium (10%Me2SO + 90% FBS) or in serum-free medium
(IBMTSTEM, Fischer Procryotect, Zurich, Switzerland) supple-
mented with 2%, 5% or 10% Me2SO [216]. The MSCs were cooled
to 80 C at 1 C/min using a standard freezing container and after
P2 h were plunged into liquid nitrogen where they were kept for
at least 24 h. No cells survived following cryopreservation in 0% or
2% Me2SO. Membrane damage from extra- and intracellular ice for-
mation and the appearance of small holes on the cell surface were
detected by multiphoton laser-scanning cryomicroscopy and scan-
ning electron microscopy, respectively. However, a reduction of
Me2SO from 10% to 5% resulted in no signiﬁcant difference in
post-thaw cell count and viability by ﬂow cytometric propidium
iodide exclusion, membrane integrity by scanning electron micro-
scopy, and tri-lineage differentiation [216]. In a similar study, the
effect of 5% Me2SO was found to be comparable to 10% Me2SO after
cryopreserving porcine bone marrow-derived MSCs (by cooling at
a rate of 1 C/min from 25 C to 80 C and immediately plunging
into liquid nitrogen where they were stored for less than a month)
in terms of survival as measured by trypan blue exclusion, and
expression of apoptosis-related genes and stem cell markers [155].
Furthermore, no signiﬁcant differences in survival rates of
human bone marrow-derived MSCs were detected when cells were
cryopreserved (by placing the cell suspension in a Mr. Frosty freez-
ing container at 80 C for 24 h then transferring to liquid nitrogen
vapor) in the presence of 10%Me2SO or 5%Me2SOwhen trehalose is
added; however, using only 2.5% Me2SO resulted in reduced viabil-
ity and proliferation after 7 days of culture as measured by trypan
blue exclusion [27]. Consistent with this result is the ﬁnding that
3% Me2SO has no protective effect on human tooth germ stem cells
that were cryopreserved by placing in a 1 C/min freezing container
at 80 C then transferring to 196 C the next day [45]. Moreover,
Me2SO concentrations under 4% are associated with reduced viabil-
ity (as measured using MTT) in rat bone marrow-derived MSCs cry-
opreserved using various controlled rate freezing protocols [152].
Addition of hydroxyethyl starch (HES), which by itself does not con-
fer protection toMSCs, can help reduceMe2SO levels as a solution of
8%Me2SO and 2% HES showed the highest post-thaw viability com-
pared to other combinations tested [152].
Recently, it was shown that the addition of sugars such as lac-
tose, sucrose, trehalose or rafﬁnose (at 300 mM concentration)
during the sub-culture and cryopreservation of human dermal
MSCs (by cooling at 1 C/min to 80 C and plunging in liquid
nitrogen) resulted in up to 60% survival even in the complete
absence of Me2SO and FBS [159]. Moreover, no signiﬁcant differ-
ences in morphology or ability to differentiate to osteogenic and
adipogenic cells were observed between unfrozen cells and cells
cryopreserved in the presence of sugars or 10% Me2SO and 20%
FBS [159].
4.3.2. Animal serum-free formulations
Most cryopreservation protocols for stem cells employ FBS at
concentrations ranging from 5% to 90%. Apart from providing nutri-
ents to cells while in culture, serum stabilizes cell membranes,
adjusts osmotic pressures and protects cells from free oxygen rad-
icals formed during cryopreservation and long-term storage.
However, animal-derived serum is not a desirable component of
cellular products for clinical applications because it carries therisks of transmitting viruses, prions or proteins that may elicit
immunological responses. Moreover, serum composition varies
with source and batch. Thus, for ethical and practical reasons, there
have been active investigations into ﬁnding well-deﬁned serum
alternatives. For example, Lonza (Basel, Switzerland) has devel-
oped Chemically Deﬁned Mesenchymal Stem Cell Growth
Medium (MSCGM-CD) which was employed recently to culture
umbilical cord-derived MSCs [208]. The cells exhibited the same
phenotype and differentiation capacity as those cultured in
serum-containing media and produced more immunomodulatory
factors.
The feasibility of using serum-free freezing solution with a
reduced amount of Me2SO (7.5%, 5% and 2.5%) in combination with
polyethylene glycol and trehalose in cryopreserving human bone
marrow-derived MSCs was also investigated by allowing cells to
equilibrate with freezing solution for 10 min at 4 C, cooling in a
freezing container at 1 C/min to 80 C, remaining at 80 C over-
night, and then storing in liquid nitrogen for at least 1 week [127].
Although non-cryopreserved MSCs have faster proliferation rates
(7 days to reach stationary growth phase vs. 9 days) compared to
their cryopreserved counterparts, both show similar patterns of
cellular morphology, intracellular pH and mitochondrial distribu-
tion. There was signiﬁcant apoptosis 2 h after thawing, but after
24 h, metabolic rates were comparable in all cryopreserved cells.
This study also indicated that in order to protect MSCs during cry-
opreservation there should be at least 5% Me2SO if it is the only
permeating cryoprotectant used. However, Me2SOmay be replaced
with another permeating cryoprotectant, such as 1,2-propanediol,
and human albumin (2%) may also be added to enhance cell sur-
vival [127].
The effects of these different freezing solutions were further
evaluated on MSCs derived from the bone marrow of mice, rats
and calves [128] using exactly the same freezing protocol as above
[127]. It was demonstrated that a serum-free medium with 5%
Me2SO, 2% polyethylene glycol, 3% trehalose and 2% albumin is bet-
ter at maintaining the cell viability (as determined by trypan blue
exclusion), metabolic activity and differentiation potential of cry-
opreserved MSCs from these species than 10% Me2SO with 10%
or 90% bovine serum [128].
Cryoprotective properties of non-toxic alternatives to Me2SO,
such as glycerol and the biocompatible solutes ectoin and proline
in the absence of serum but in the presence of methylcellulose,
were also compared [149]. Glycerol protects from osmotic damage
by reducing intra- and extracellular ice formation; ectoin protects
against high salt concentration by acting as an osmolyte; and pro-
line is an amino acid that can diffuse through cells and act as a cry-
oprotectant. Different concentrations of glycerol (5%, 10% and 20%),
ectoin (1%, 5% and 10%) and proline (1%, 5% and 10%) were used to
freeze (by cooling at 1 C/min to a ﬁnal temperature of 80 C) a
human MSC cell line and found to be non-toxic for up to 60 min
incubation and at all concentrations tested. However, only ectoin
conferred protection resulting in a high post-thaw survival of up
to 72% according to trypan blue exclusion, suggesting that it is pos-
sible to cryopreserve MSCs in the absence of Me2SO and serum
[79]. Because a combination of two compatible solutes is more
effective than each solute by itself, a human MSC cell line was cry-
opreserved in a basal freezing medium consisting of PBS and 0.1%
methylcellulose and varying concentrations of ectoin and proline
or using the commercial Me2SO-free freezing solution Biofreeze
(Biochrom, Berlin, Germany) [68]. The cells were pre-equilibrated
with the freezing medium for 10 or 60 min on ice and cooled at
1 C/min or 5 C/min or 10 C/min to 150 C at which they were
stored for at least 3 days. A pre-freezing incubation time of
60 min in 1% proline/10% ectoin and a cooling rate of 10 C/min
gave a high survival 48 h post-thaw (about 90%) but the highest
survival (nearly 99%) was attained using Biofreeze [68].
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neuropeptides (vasoactive intestinal peptide, glucose-dependent
insulinotropic peptide, and pituitary adenylate cyclase activating
polypeptide) have been used as alternatives [27]. High post-thaw
viability (about 80% by trypan blue exclusion) was attained when
human bone marrow-derived MSCs were cryopreserved (by plac-
ing directly in a freezing container at 80 C and transferring to
liquid nitrogen vapor after 24 h) in the presence of 5% Me2SO,
30 mM trehalose and 8% human albumin. However, the enhancing
effects of neuropeptides on cell survival and proliferation rates
after cryopreservation still required the presence of FBS [27].
Instead of animal serum, human albumin (5%) and Me2SO (5%)
were used to cryopreserve the MSC-containing stromal vascular
fraction from adipose tissues under controlled rate conditions
(comprising of cooling from 4 C to 0 C in 6 min, then holding
for 15 min at 0 C; cooling from 0 C to  C in 9 min, holding for
2 min at 2 C; cooling from 2 C to 35 C in 25.5 min, and
ﬁnally cooling from 35 C to 100 C in 13 min) [146]. The cells
were kept frozen for 14–193 days. The post-thaw viability as mea-
sured by 7-amino-actinomycin D (7AAD) ﬂow cytometric analysis
ranged from 71.7% to 98.3% and cells maintained their growth and
differentiation to mesenchymal-speciﬁc lineages [146].4.3.3. Sugars, anti-oxidants, apoptotic inhibitors and other additives
Some of the damage induced in cells during freezing can be
attributed to dehydration, the production of oxygen radicals and
the activation of apoptosis enzymes such as caspases. Therefore,
the effect on cell survival of addition of trehalose (a sugar that
can stabilize cell membranes by interacting with lipoproteins),
catalase (an antioxidant) and zVAD-fmk (a general caspase inhibi-
tor) in the cryopreservation solution has been investigated [185].
Amniotic ﬂuid-derived MSCs were added to a serum-free freezing
medium containing varying concentrations of Me2SO (2.5%, 5%
and 10%) and 60 mM trehalose, 100 lg/mL catalase and 30 lM
zVAD-fmk, then cooled using a controlled rate freezer (unspeciﬁed
cooling rate) and stored in liquid nitrogen for a minimum of
3 weeks. The population doubling, cell surface antigen expression
and myogenic differentiation potential were similar in MSCs cry-
opreserved in 2.5% Me2SO in the presence of the three additives
compared to MSCs frozen in 10% Me2SO and 30% FBS [185].
These results suggest that it is possible to reduce the amount of
Me2SO and eliminate serum in the cell freezing solutions and still
maintain the viability and function of cryopreserved MSCs.
Surface-active compounds play important roles in vivo in the
assembly and function of many biological structures such as the
cell membrane where they have a tendency to be adsorbed at
the surface. Pluronic F68 is a non-ionic low-foaming surfactant
that has been shown to have protective effects on eukaryotic cell
lines during their cryopreservation by stabilizing the cell mem-
brane [78]. One group tested the effect of Pluronic 188 (F68) on
MSCs during cryopreservation [50]. Human tooth germ stem cells
were cryopreserved in freezing medium containing 10% Me2SO,
20% FBS and 0.05% F68 by uncontrolled cooling at 20 C for
15 min, then placing at 80 C overnight before plunging into liq-
uid nitrogen. Cells were thawed 1 day or 6 months later and
assessed for viability by trypan blue exclusion, expression of apop-
totic genes and differentiation-speciﬁc genes and subjected to fatty
acid proﬁling [50]. F68 was found to increase cell viability and sur-
vival by inhibiting the expression of apoptotic genes Bax, caspase-3
and p53; however, F68 did not alter the alkaline phosphatase activ-
ity, the expression of collagen and osteocalcin and the differentia-
tion potential after cryopreservation. It was suggested that a
possible cryoprotective role of F68 on the survival of MSCs may
be attributed to an alteration of lipid composition that stabilized
the cell membrane [50].Boron deﬁciency in plant cells is characterized by disruptions in
the cell wall and membrane integrity; in animals, boron is a
micronutrient required for bone maintenance. The same group
referenced above [50] studied the effect of boron (in the form
of sodium pentaborate pentahydrate) on the survival of
dental-derived MSCs after long-term cryopreservation (storage in
liquid nitrogen for 6 months) [45]. The MSCs were cooled at a rate
of 1 C/min to 80 C before plunging into liquid nitrogen. They
found that addition of borate at a concentration of 20 lg/mL to
the cryopreservation solution containing 5% Me2SO did not alter
the surface antigen expression of MSCs, but enhanced their viabil-
ity (as measured using the spectrophotometric MTS CellTitre96
assay kit) and osteogenic and chondrogenic differentiation [45].
The positive effect of boron on cell survival was attributed to an
increase in the osmolality of the freezing medium causing cells
to shrink and dehydrate rapidly thus preventing the deleterious
effects of intracellular ice formation [45].
4.3.4. Programmed freezing in a magnetic ﬁeld
The formation of intracellular ice when cells are cooled can have
extremely damaging effects as described above. Based on the pre-
mise that magnetically-induced mechanical oscillations can pre-
vent ice crystal formation by non-thermal vibration [112], a
protocol was developed whereby murine bone marrow-derived
MSCs were frozen in the presence of 10% Me2SO at different plunge
temperatures (20 C, 30 C or 40 C), using various hold times
(0, 5, 15 or 25 min) at 5 C, and increasing intensity of magnetic
ﬁeld (0.005, 0.1 and 0.2 mT) at a plunging temperature of 30 C
and a 15-min hold time at 5 C [113]. The cells were then kept
at 150 C for 7 days, thawed and cultured for 48 h. Post-thaw sur-
vival was highest (60.8%) when the plunge temperature was
30 C [113]. If the plunge temperature is higher than the optimal
temperature, cells are damaged by intracellular ice formation but if
the plunge temperature is too low, the cells are damaged by exces-
sive dehydration [162]. The highest survival rate (75.8%) was also
attained when the cells were held for 15 min. If the hold time is
too short, the Me2SO does not have enough time to permeate the
cell, but if the hold time is too long, the cells are damaged by
cytotoxic effects of Me2SO. Overall, high survival and proliferation
rates and maintenance of both adipogenic and osteogenic differen-
tiation abilities were attained at a hold time of 15 min at 5 C, a
plunge temperature of 30 C and a magnetic ﬁeld intensity of
0.1 mT [113].
4.3.5. Vitriﬁcation
Vitriﬁcation, a process whereby a viscous liquid solution is
transformed into a glass-like state (an amorphous solid without
any ice formed), has been employed as an alternative to freezing
for cryopreservation. Vitriﬁcation can be achieved by exposure to
high concentrations (>6 M or 50% by weight) of cryoprotectants
and rapid cooling [61,101]. Compared to the slow freezing method
of cryopreservation, vitriﬁcation is a necessity for delicate systems
that cannot tolerate the presence of ice. Biologics that are typically
cryopreserved using vitriﬁcation include embryos [169], oocytes
[201], articular cartilage [101], and potentially organs such as kid-
ney [61]. Table 2 shows studies employing vitriﬁcation as a means
of cryopreserving MSCs from various tissue sources. Vitriﬁcation
was applied to human amnion-derived MSCs because these cells
were unable to survive the damage of ice formation that accompa-
nies slow freezing [148]. The cells were vitriﬁed using a 2-step
loading method consisting of an equilibration step in 20% ethylene
glycol for 5 min at room temperature followed by vitriﬁcation in
40% ethylene glycol, 18% Ficoll, 0.3 M sucrose and 20% FBS. The cell
suspension was cooled at a rate of 2500–5000 C/min attained by
plunging directly into liquid nitrogen. The vitriﬁed MSCs showed
post-thaw viability of 84.3 ± 3.2% as determined by trypan blue
Table 2
Studies on vitriﬁcation of MSCs.
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terms of morphological characteristics, expression of surface anti-
gens and embryonic stem cell markers and tri-lineage differentia-
tion under appropriate culture conditions [148].
Instead of the cryoprotectants used in the vitriﬁcation method
described above, an equilibration solution containing 10% Me2SO,
10% ethylene glycol and 0.1 M sucrose and vitriﬁcation solution
with 20% Me2SO, 20% ethylene glycol and 0.5 M sucrose, was used
to vitrify human fetal liver-derived MSCs [194]. The equilibration
and addition steps were both carried out at room temperature.
The mean recovery of viable cells (86 ± 4.7% as assessed by trypan
blue exclusion) was comparable to that obtained using the original
vitriﬁcation procedure (84.2 ± 4.8%) although it was lower than
that of non-vitriﬁed control (93.5 ± 1.7%). The morphological
appearance, expression of surface markers and differentiation to
adipocytes and osteocytes were unaffected by the vitriﬁcation pro-
cedure [194].
Because existing protocols for vitriﬁcation use high concentra-
tions of cryoprotectants which can be cytotoxic, additives have
been used to mitigate damaging effects. One such compound is
polyvinyl alcohol (PVA), a non-permeating cryoprotectant which
has been previously proven to inhibit ice crystal formation and
growth [204]. MSCs derived from sheep umbilical cord blood were
vitriﬁed in a solution containing 5% ethylene glycol, 35% propylene
glycol, 5% sucrose and 1% PVA using the Opened Pulled Straw
technique [201]. Cell viability as high as 95.4% was obtained using
trypan blue exclusion, which was comparable to that obtained
with non-vitriﬁed control [205].
The same two-step vitriﬁcation method described above [148]
was used to cryopreserve MSCs from human umbilical cord
Wharton’s jelly. The expression of surface antigens and
tri-lineage differentiation were retained in the vitriﬁed cells com-
pared to their non-vitriﬁed counterparts and a post-thaw viability
of 95.54 ± 2.30% was attained by trypan blue staining [138]. More
recently, this group demonstrated that vitriﬁcation does not alter
the differentiation of these cells to male germ-like cells based on
their protein expression of germ cell-speciﬁc markers [109].4.3.6. Use of 3D scaffolds
Cryopreservation of MSCs adhering to fabricated scaffolds of
biocompatible materials is a strategy that has been explored to pre-
pare ready-to-use transplantation units for the repair of damage in
bone, cartilage or skin. In order to overcome the difﬁculty offreezing adherentmonolayers and to simulate the 3D conformation
that exists in vivo, MSCs have been cryopreserved in encapsulated
form in alginate microspheres. Alginate is a natural polysaccharide
that offers the advantage of biocompatibility and biodegradability.
Moreover, alginate is hygroscopic and by absorbing water can pre-
vent the formation of large ice crystals during the freezing process.
Suspended or alginate-encapsulated bone marrow-derived MSCs
were cryopreserved in 5% or 10% Me2SO by linear cooling at
1 C/min to 80 C before plunging into liquid nitrogen [165]. The
percent viability was assessed by confocal microscopy after stain-
ing cells with a combination of ﬂuorescein diacetate (FDA) and
ethidium bromide (EB). The viability and metabolic activity of
MSCs in suspension were found to be higher than their encapsu-
lated counterparts in the presence of 5% Me2SO, but were the same
in 10%Me2SO, whichmay be due to the slower suboptimal distribu-
tion of the Me2SO in the hydrogel. By using a 3-step freezing proce-
dure (comprising of a 1 C/min cooling from 0 C to 7 C at which
point ice nucleationwas induced, followed by cooling at 1 C/min to
40 C, and ﬁnally a 10 C/min cooling to 80 C before plunging
into liquid nitrogen) post-thaw viabilities of 90% were obtained
for alginate-encapsulated MSCs cryopreserved in the presence of
10% Me2SO. These encapsulated cells exhibited tri-lineage differen-
tiation [165].
In order to further optimize this methodology, the attachment
and spreading of MSCs within an alginate–gelatin scaffold prior
to cryopreservation was investigated [108]. Umbilical
cord-derived MSCs were seeded for 2 h in the scaffold, and the
cell–scaffold complex was held in 10% Me2SO for 5 min at 4 C fol-
lowed by cooling at a rate of 1 C/min to 80 C where it was kept
overnight before plunging into liquid nitrogen. Viability was
assessed by confocal laser scanning microscopy of FDA/EB labeled
cells, and the attachment of cells to the scaffold as well as cell
membrane disruptions were visualized using scanning electron
microscopy. The cell viability, cell contacts, membrane integrity,
motility and spreading were shown to be comparable to the
non-frozen control [108]. Furthermore, tissue-engineered con-
structs developed from umbilical cord-derived MSCs in electro-
spun silk ﬁbroin scaffold were successfully cryopreserved using a
freezing medium consisting of trehalose (40 mM), ectoin
(40 mM), catalase (100 lg) and Me2SO (2.5%). The viability (based
on propidium iodide staining), proliferation and differentiation of
MSCs, and the mechanical integrity of the scaffold were similar
to those of their non-cryopreserved counterpart [24]. Table 3
Table 3
Studies on cryopreservation of MSCs in scaffolds.
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folds, which indicate that the use of 3D scaffolds is feasible and
presents potential applications for tissue-engineered cryopre-
served cells in regenerative therapies.5. Cryopreservation of tissues from which MSCs are derived
The desired scenario for regenerative medicine and tissue engi-
neering includes a ready availability of clinically acceptable MSCs.
As the tissue sources of MSC may not always be accessible on short
notice, it may become necessary to cryopreserve tissues as they
become available. In addition, some facilities lack the personnel
and equipment that would otherwise be required to start the cul-
tures at the very moment that the tissues are received. Moreover,
because changes in gene expression occur immediately after isola-
tion and persist during their monolayer expansion [14], it would be
ideal to establish MSC cultures from the same donor tissue at pas-
sage 0 instead of using cells that have undergone long-term cul-
ture. Cryopreservation of the tissues from which the MSCs are
derived, and initiating their isolation and culture at a later time,
is a practical approach to circumvent these issues. The question
that arises is whether the MSCs that are recovered from the frozen
tissues will have the same functional properties as those isolated
from fresh non-cryopreserved tissues. Several groups have com-
pared MSCs isolated from fresh vs. cryopreserved tissues including
bone marrow, umbilical cord, adipose tissue, dental pulp and intact
teeth [10,34,39,122,124,158,178,187] (Table 4).
Bone marrow has been the original and traditional source of
MSCs, although its cryopreservation has been performed primarily
for the purpose of preserving the hematopoietic stem/progenitor
cell populations for transplantation. Previously it has been shown
that MSCs obtained from bone marrow mononuclear cells that
have been cryopreserved for 4–8 weeks exhibit similar surface
markers, proliferation potential and differentiation capacity to
their counterparts from fresh bone marrow [34]. More recently,
bone marrow cells (from autologous transplant patients) that have
been cryopreserved for over 20 years were thawed and used to
establish MSC cultures [187]. The cryopreservation protocol
involved pre-incubation in freezing solution containing 10%
Me2SO and 10% autologous plasma in media for 30 min at 4 C, fol-
lowed by controlled rate freezing at 1 C/min from 4 C to 50 C
and at 10 C/min from 50 C to 80 C before immersion in liquid
nitrogen. Although the number of adherent of cells in the initial
cultures after thawing was only 50% of the seeded cells compared
to those from fresh bone marrow, the cells were able to recover
under appropriate culture conditions and displayed similarmorphology, cell growth patterns, cell surface marker expression
and differentiation into osteogenic and adipogenic cells as MSCs
established from fresh bone marrow samples [187].
MSCs harvested from theWharton’s jelly of umbilical cord exhi-
bit greater proliferative potential than bone marrow-derived MSCs
[122] which makes Wharton’s jelly an ideal MSC source. In one
study, segments of umbilical cord (2–3 cm)were immersed inmed-
ium containing 10% Me2SO and 0.2 M sucrose and cooled at 1/min
to 80 C [178]. After overnight incubation, the frozen tissue was
transferred to liquid nitrogen and kept for 5–29 days. After quick
thawing at 37 C, the cord tissue was cultured as explants until cells
started to emerge and form a conﬂuent layer. The growth kinetics,
surface antigen expression and differentiation of MSCs to adipo-
cytes and chondrocytes were compared to those for MSCs obtained
from non-cryopreserved explants from the same donor. Although
MSCs took longer to grow out of the cryopreserved cord explants
as compared to corresponding fresh explants, no signiﬁcant change
in population doublings were observed between them. The MSCs
derived from cryopreserved tissue were likewise capable of
in vitro differentiation and expressed the same surface markers,
although their cumulative cell yield at the end of the third passage
was lower than that from fresh umbilical cord samples [178].
Similarly, cord tissue was suspended in 10% Me2SO and 20% cord
plasma for 30 min at 4 C and cooled using a controlled rate freezer
to 180 C (unspeciﬁed cooling rate) where it was kept for 5 years.
After thawing, the tissues yieldedMSCs with poor plating efﬁciency
albeit with good functional recovery [10]. In contrast, one group
reported failure to isolate MSCs from umbilical cord fragments cry-
opreserved in medium containing 10% Me2SO, 5% glycerol and 20%
FBS [35]. The tissues were allowed to equilibrate in the freezing
medium for 30 min at 4 C before placing in a freezing container
designed for cooling at 1 C/min to80 C, and then stored in liquid
nitrogen for 1 week, 1 month or 6 months [35].
In another study, adipose tissue was harvested from patients
undergoing liposuction procedures and samples from each patient
were either processed within 24 h or frozen for at least a week
[39]. The cryopreservation protocol involved putting the adipose
tissue in 4 mL media containing 10% Me2SO and 10% FBS at 4 C,
cooling in a controlled rate freezer (unspeciﬁed cooling rate), and
submerging in liquid nitrogen. MSCs were successfully isolated
from all of the fresh and frozen adipose tissues. The morphology,
doubling time, plating efﬁciency, expression of phenotypic mark-
ers, and adipogenic, osteogenic, and chondrogenic differentiation
of the MSCs were not compromised by cryopreservation nor was
there any signiﬁcant effect on the senescence of MSCs [39].
Dental pulp is another promising source of MSCs for cellular
therapy and tissue engineering applications. It has been shown
Table 4
Studies on cryopreservation of source tissues of MSCs.
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Me2SO, cooled at 1 C/min to 85 C before plunging into liquid
nitrogen) of early passage MSCs from dental pulp leads to a high
post-thaw recovery of viable cells as assessed by trypan blue exclu-
sion [158]. The same group then attempted to cryopreserve dental
pulp by placing enzyme-digested tissue in 10% Me2SO and cooling
at 1 C/min before storing for at least a month in liquid nitrogen
[207]. Intact teeth or undigested dental pulp tissue were also
frozen by direct immersion into 10%Me2SO for 2 h at 4 C, followed
by cooling at 1 C/min in an isopropanol bath within a 85 C
mechanical freezer for 24 h before plunging into liquid nitrogen
where they were stored for at least a month. The best recovery
of MSCs was achieved by cryopreserving the dental pulp tissue
with enzymatic digestion and cell isolation carried out
post-thaw. Growth of MSCs from pre-digested tissue was delayed
and only 2 out of 10 frozen intact teeth yielded MSCs [207].
Similarly, only a 30% success rate was achieved when establishing
MSC cultures from cryopreserved deciduous teeth [124]. The teeth
were immersed in 1.5 mL of 10% Me2SO/90% FBS, equilibrated at
4 C for 1 h, cooled at 1 C/min to 80 C where they were kept
for 24 h before storing in liquid nitrogen for 7 days. The MSCs
recovered from thawed teeth displayed lower proliferation rate
and altered morphology [124].6. Current status of cryopreserved MSCs for the clinic
Cryopreservation and banking under safe and quality-
controlled conditions are crucial to the implementation and
success of cell-based therapies [54]. Tremendous research, regula-
tory and industrial resources have been expended towards
optimizing the protocols, freezing media composition, cooling
devices and storage containers in order to ensure that MSCs
retain their therapeutic characteristics after freeze/thaw [95,193].The market approval of the cryopreserved MSC drug Prochymal
by Health Canada in 2012, based on compelling phase II clinical
trial results showing statistically signiﬁcant improvement in sur-
vival among patients with severe refractory GVHD [25], may be
considered the culmination of these efforts. Lately however, doubt
has been cast upon the efﬁcacy of this cellular product based pri-
marily on the erroneous assumption that immediate post-thaw
MSCs possess the same features as their pre-freeze counterparts
[72]. A phase III industry-sponsored clinical trial (NCT00366145)
on Prochymal conducted in the USA and licensed by the Food
and Drug Administration failed to meet its primary clinical end-
point of achieving an increased GVHD overall complete response
compared with placebo control [71]. This trial outcome does not
support the clinical use of MSCs and is not consistent with pub-
lished European clinical experience which claimed that multiple
MSC infusions are effective in children with GVHD [12]. These con-
ﬂicting trial outcomes raised the question of the appropriateness of
MSCs for clinical application and also brought to light putative
problems associated with MSC-based therapy, including immedi-
ate cell death upon infusion, poor homing capacity, increased risk
of infection and leukemic relapse, among others [104].
Notwithstanding, it is claimed that MSC therapy beneﬁted some
patients to a certain degree; and although a myriad of factors could
be put forth to explain why it failed in others, here we will consider
only those related to the culture and cryopreservation of MSCs.
The company website of Prochymal (http://www.osiris.com)
describes this product as being harvested from a single healthy
bone marrow donor from which 10,000 doses can be derived.
This would entail massive expansion and most likely increased
number of passaging. In contrast, the European-based clinical trials
typically harvest a number of cells equivalent to 5–10 doses per
donor [71]. It has been previously shown that late passage MSCs
are not as effective as their early passage counterparts in treating
GVHD [11]. Recently, it was demonstrated that freeze–thawed
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immunomodulatory properties and that patients infused with
freshly harvested cells from early passage cultures had better
response rates [147]. Moreover, it is noteworthy that the retro-
spective study reporting favorable outcomes of MSC infusions in
children with GVHD [12] involved transfusions of MSCs in their
log phase of growth. In contrast, Prochymal was administered
either immediately or up to 5 h after thaw by reconstituting the
frozen product. Taken together, these factors may explain why
the US-based phase III clinical trial, which used Prochymal, failed
to reach its desired endpoint.
It is empirically known that a signiﬁcant loss (about 20%) in the
recovery of viable cells occurs after cryopreservation. Apoptotic
and necrotic pathways are activated in cells 6–48 h post-thaw in
response to low temperature exposure [17], and cryopreserved
MSCs have a higher percentage of apoptotic cells than MSCs from
fresh live cultures [38]. It has also been shown that thawed MSCs
launch a ‘‘heat shock’’ response to the stress associated with
cryopreservation which results in a dampening of their
immune-suppressive properties [67,72,147]. Moreover, although
cryopreservation does not alter the expression of adhesion mole-
cules and homing receptors such as CXCR4 in MSCs, it disrupts
F-actin polymerization [212,213] and reduces their homing to
lungs [38]; however, a 48-h culture of post-thaw MSCs restores
their homing ability [38,72]. It may therefore be necessary to allow
the cells to recover ﬁrst before they are infused. In support of this
notion, human bone marrow-derived MSCs which were
sub-cultured up to passage 3 were cryopreserved in 10% Me2SO
by cooling at 1 C/min to 80 C and plunging immediately into
liquid nitrogen [93]. The cells thawed after 1, 3, 6, 7, and 8 months,
not only attained 20-fold expansion after 5–8 days, but most
importantly, their immunosuppressive properties were retained
[93]. It has also been shown in adipose-derived MSCs that, instead
of the harsh enzymatic or chemical treatment used to dislodge the
cells which can strip them of important surface receptors, the cells
can be cultured in synthetic hydrogels which permit reagent-free
passaging while preserving their phenotype and potency [53].
Thus, while viable MSCs can be obtained from certain cryopre-
served tissues, the isolation and cryopreservation of MSCs from
fresh tissues present some beneﬁt.7. Conclusions
MSCs are favored above embryonic or induced pluripotent stem
cells as a candidate cellular therapy product because of their easy
availability and minimummanipulation. In addition, a comprehen-
sive and systematic review of reported adverse events in clinical
trials using MSCs show that their systemic infusion is safe and car-
ries no risk of malignant transformation [117]. Cytogenetic aberra-
tions were not observed in fresh and cryopreserved human
bone-marrow derived MSCs cultured under xenogen-free GMP
conditions [130]. Presuming positive outcome of clinical trials,
MSC-based therapy could become the standard of care in patients
with various injuries and disorders, but rigorous evidence of their
efﬁcacy remains to be proved.
It is apparent from the studies reported so far that viable and
functional MSCs can be recovered following cryopreservation
regardless of the tissue from which the MSCs are derived, using a
wide variety of cooling protocols, added cryoprotectants, storage
times and temperatures. Some cells inevitably die as a result of
the freeze–thaw process while others have alterations in their bio-
logical properties which affect their therapeutic potential [164].
However, those cells that survive retain their proliferative poten-
tial and are able to generate large numbers of fully functional cells.
In fact, it has been demonstrated that MSCs express proteinsinvolved in replication and cellular defense mechanisms in
response to the stress of cryopreservation that may contribute to
their survival and recovery during freeze–thaw [77].
In light of the negative outcome of clinical trials that employed
cryopreserved MSCs for infusion, we and others recommend that
cryopreserved MSCs should be allowed to recover longer after
thaw [38,67,93]. Also, because washing of cells after thawing can
lead to cell loss, a better approach may be to plate the cells imme-
diately after thaw (which involves some dilution of the cryoprotec-
tant), and then to allow them to expand to conﬂuency. Passaging
will remove the residual cryoprotectant and animal-derived
serum, and the cells can then be further cultured in animal
serum-free medium or supplemented with human platelet lysate
[19] or platelet-rich plasma in a Good Manufacturing Practice
(GMP)-compliant lab [161,184]. The ﬁnal cellular product could
be delivered to the patient’s bedside for infusion. Alternatively, it
has been shown that sub-conﬂuent cultures of MSCs that have
been stored hypothermically at 4 C for 2–4 days and then allowed
to recover at 37 C for 3 h yielded cells with normal proliferation,
surface marker expression and osteogenic potential [76].
Moreover, the addition of chemical modulators such as resveratrol
and salubrinal decreased apoptosis, necrosis and the levels of cell
stress signaling proteins, thereby improving the viability of human
MSCs following hypothermic storage [41].
Translating research-based procedures into large-scale manu-
facturing requires strict compliance with regulations to ensure
the identity, safety, genetic stability, potency and efﬁcacy of
MSCs for use in the clinic [54,183,184,206,209]. Because massive
expansion of MSCs would be needed to attain therapeutic doses,
it is not practical to use conventional culture methods which will
require hundreds of culture ﬂasks and many open procedures. In
response to this need, closed system large-scale bioreactors are
becoming available [54,85,86]. As 2D expansion negatively affects
MSC proliferation potential, successful MSC expansion has been
achieved using growth factor stimulation and reduced oxygen ten-
sion in 3D bioreactors [92]. Also, spinner ﬂask cultures using syn-
thetic microcarriers under xeno-free conditions have allowed for a
3D environment in the scalable and cost-effective expansion of
MSCs [33,88].
Finally, the success of MSC-based therapies would rely on cells
whose proliferative capacity, differentiation potential, secretory
proﬁle, migration ability and immunomodulatory properties
remain intact following cryopreservation. The efﬁcacy of MSCs
should be based on cell functionality, and assays predictive of
potency for the appropriate clinical application must be employed
and used as release criteria [73,210]. Future investigations should
focus on the recovery and rescue of cells from
freeze/thaw-associated injury followed by the expansion of fully
functional cells and correlation of post-thaw cell handling with
outcome studies. Moreover, the robustness displayed by MSCs in
response to cryopreservation makes them an ideal cell source for
tissue-engineered constructs for the repair or regeneration of dis-
eased or damaged tissues. The cryopreservation of these constructs
could be another focus of future research.Acknowledgments
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